Last update:

Medications news

Medications

Study reveals cost differences between Medicare Advantage and traditional Medicare patients in cancer drugs

A new study examining the use of high-cost drugs among patients with colorectal cancer and non-small cell lung cancer found those insured through Medicare Advantage received less expensive cancer drugs compared to others ...

Medications

Medicare rules may reduce prescription steering

Weill Cornell Medicine researchers have found that pharmacy benefit managers (PBMs)—organizations that negotiate access to medicines for most patients in the United States—steer patients to use their own pharmacies. However, ...

Medications

New drug for prostate cancer patients in clinical trials

Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical trials for ovarian and bile duct cancer, according to research published in the journal Clinical ...

Medications

Talquetamab plus teclistamab shows promise in multiple myeloma

For patients with relapsed or refractory multiple myeloma, talquetamab plus teclistamab shows response in a high percentage of patients and a higher incidence of grade 3 or 4 infections than with either therapy alone, according ...

Medications

DoxyPEP use linked to sharp decline in STI cases

A new study has found that rates of chlamydia and syphilis plummet among people prescribed doxycycline for sexually transmitted infection prevention in routine clinical care.

Medications

How legal pot may be reducing opioid prescriptions

In states where medical marijuana is legal, payments from opioid manufacturers to physicians have decreased significantly—suggesting that marijuana may be emerging as a viable alternative to opioids for pain management, ...

Medications

FDA approves Cobenfy for adults with schizophrenia

The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic agonist, for the treatment of schizophrenia in adults.

Medications

European watchdog partially approves new Alzheimer's drug

Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer's disease, reversing an earlier decision not to give it the green light.